Could a diabetes drug boost chemo for ovarian cancer?

NCT ID NCT02122185

First seen Apr 03, 2026 · Last updated Apr 30, 2026 · Updated 3 times

Summary

This study tested whether adding metformin, a common diabetes medicine, to standard chemotherapy helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer. 111 participants received either metformin or a placebo alongside their chemo, then continued metformin as maintenance. The goal was to see if metformin could slow cancer growth and improve treatment response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN ENDOMETRIOID ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, 62526, United States

  • Ingalls Memorial Hospital

    Harvey, Illinois, 60426, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Mitchell Cancer Institute - University of South Alabama

    Mobile, Alabama, 36604, United States

  • NCH Medical Group- Northwest Community Hospital

    Arlington Heights, Illinois, 60005, United States

  • NorthShore University HealthSystem

    Evanston, Illinois, 60201, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • University of Alabama

    Birmingham, Alabama, 35233, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.

BRENNER TUMOR MALIGNANT ASCITES MALIGNANT ASCITES MALIGNANT PLEURAL EFFUSION OVARIAN CLEAR CELL CYSTADENOCARCINOMA OVARIAN ENDOMETRIOID ADENOCARCINOMA OVARIAN MIXED EPITHELIAL CARCINOMA OVARIAN SEROUS CYSTADENOCARCINOMA OVARIAN UNDIFFERENTIATED ADENOCARCINOMA OVARIAN UNDIFFERENTIATED ADENOCARCINOMA RECURRENT FALLOPIAN TUBE CANCER RECURRENT OVARIAN EPITHELIAL CANCER RECURRENT OVARIAN GERM CELL TUMOR RECURRENT PRIMARY PERITONEAL CAVITY CANCER STAGE IIIA FALLOPIAN TUBE CANCER STAGE IIIA FALLOPIAN TUBE CANCER STAGE IIIA OVARIAN EPITHELIAL CANCER STAGE IIIA OVARIAN EPITHELIAL CANCER STAGE IIIA OVARIAN GERM CELL TUMOR STAGE IIIA OVARIAN GERM CELL TUMOR STAGE IIIA PRIMARY PERITONEAL CAVITY CANCER STAGE IIIA PRIMARY PERITONEAL CAVITY CANCER STAGE IIIB FALLOPIAN TUBE CANCER STAGE IIIB FALLOPIAN TUBE CANCER STAGE IIIB OVARIAN EPITHELIAL CANCER STAGE IIIB OVARIAN EPITHELIAL CANCER STAGE IIIB OVARIAN GERM CELL TUMOR STAGE IIIB OVARIAN GERM CELL TUMOR STAGE IIIB PRIMARY PERITONEAL CAVITY CANCER STAGE IIIB PRIMARY PERITONEAL CAVITY CANCER STAGE IIIC FALLOPIAN TUBE CANCER STAGE IIIC FALLOPIAN TUBE CANCER STAGE IIIC OVARIAN EPITHELIAL CANCER STAGE IIIC OVARIAN EPITHELIAL CANCER STAGE IIIC OVARIAN GERM CELL TUMOR STAGE IIIC OVARIAN GERM CELL TUMOR STAGE IIIC PRIMARY PERITONEAL CAVITY CANCER STAGE IIIC PRIMARY PERITONEAL CAVITY CANCER STAGE IV FALLOPIAN TUBE CANCER STAGE IV FALLOPIAN TUBE CANCER STAGE IV OVARIAN EPITHELIAL CANCER STAGE IV OVARIAN EPITHELIAL CANCER STAGE IV OVARIAN GERM CELL TUMOR STAGE IV OVARIAN GERM CELL TUMOR STAGE IV PRIMARY PERITONEAL CAVITY CANCER STAGE IV PRIMARY PERITONEAL CAVITY CANCER